Loading...
Market
Will FluMist nasal spray receive any safety-related recalls or warnings by the FDA by September 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and official recalls
Story
FDA Approves First-of-its-Kind At-Home FluMist Nasal Spray
Sep 20, 2024, 07:52 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self-administration or caregiver-administration. This approval marks the first time a flu vaccine can be administered at home without the need for a healthcare provider, making it the first of its kind. FluMist is licensed for individuals aged 2 to 49 and will be available through third-party pharmacies where users will complete a screening and eligibility assessment. The FDA's decision is part of a broader effort to expand consumer access to medicines and reduce healthcare costs and barriers.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%